Tai Chi for coronavirus disease 2019 in recovery period: A protocol for systematic review and meta analysis.


Journal

Medicine
ISSN: 1536-5964
Titre abrégé: Medicine (Baltimore)
Pays: United States
ID NLM: 2985248R

Informations de publication

Date de publication:
07 Aug 2020
Historique:
entrez: 10 8 2020
pubmed: 10 8 2020
medline: 15 8 2020
Statut: ppublish

Résumé

Assessing the effectiveness and safety of Tai Chi for coronavirus disease 2019 (COVID-19) in recovery period is the main purpose of this systematic review protocol. The following electronic databases will be searched from inception to April 2020: MEDLINE, Ovid, EMBASE, the Cochrane Library, the Allied and Complementary Medicine Database, Chinese National Knowledge Infrastructure, Chinese Biomedical Literature Database, VIP Database and Wanfang Database. In addition, Clinical trial registries, like the Chinese Clinical Trial Registry, the Netherlands National Trial Register and ClinicalTrials.gov, will be searched for ongoing trials with unpublished data. No language restrictions will be applied. The primary outcome will be the time of disappearance of main symptoms (including fever, asthenia, cough disappearance rate, and temperature recovery time), and serum cytokine levels. The secondary outcome will be the accompanying symptoms (such as myalgia, expectoration, stuffiness, runny nose, pharyngalgia, anhelation, chest distress, dyspnea, crackles, headache, nausea, vomiting, anorexia, diarrhea) disappear rate, negative COVID-19 results rate on 2 consecutive occasions (not on the same day), CT image improvement, average hospitalization time, occurrence rate of common type to severe form, clinical cure rate, and mortality. Two independent reviewers will conduct the study selection, data extraction and assessment. Review manager software V.5.3 will be used for the assessment of risk of bias and data synthesis. The results will provide a high-quality synthesis of current evidence for researchers in this subject area. The conclusion of the study will provide an evidence to judge whether Tai Chi is effective and safe for COVID-19 in recovery period. This protocol will not evaluate individual patient information or infringe patient rights and therefore does not require ethical approval. Results from this review will be disseminated through peer-reviewed journals and conference reports.PROSPERO registration number CRD42020181456.

Sections du résumé

BACKGROUND BACKGROUND
Assessing the effectiveness and safety of Tai Chi for coronavirus disease 2019 (COVID-19) in recovery period is the main purpose of this systematic review protocol.
METHODS METHODS
The following electronic databases will be searched from inception to April 2020: MEDLINE, Ovid, EMBASE, the Cochrane Library, the Allied and Complementary Medicine Database, Chinese National Knowledge Infrastructure, Chinese Biomedical Literature Database, VIP Database and Wanfang Database. In addition, Clinical trial registries, like the Chinese Clinical Trial Registry, the Netherlands National Trial Register and ClinicalTrials.gov, will be searched for ongoing trials with unpublished data. No language restrictions will be applied. The primary outcome will be the time of disappearance of main symptoms (including fever, asthenia, cough disappearance rate, and temperature recovery time), and serum cytokine levels. The secondary outcome will be the accompanying symptoms (such as myalgia, expectoration, stuffiness, runny nose, pharyngalgia, anhelation, chest distress, dyspnea, crackles, headache, nausea, vomiting, anorexia, diarrhea) disappear rate, negative COVID-19 results rate on 2 consecutive occasions (not on the same day), CT image improvement, average hospitalization time, occurrence rate of common type to severe form, clinical cure rate, and mortality. Two independent reviewers will conduct the study selection, data extraction and assessment. Review manager software V.5.3 will be used for the assessment of risk of bias and data synthesis.
RESULTS RESULTS
The results will provide a high-quality synthesis of current evidence for researchers in this subject area.
CONCLUSION CONCLUSIONS
The conclusion of the study will provide an evidence to judge whether Tai Chi is effective and safe for COVID-19 in recovery period.
ETHICS AND DISSEMINATION BACKGROUND
This protocol will not evaluate individual patient information or infringe patient rights and therefore does not require ethical approval. Results from this review will be disseminated through peer-reviewed journals and conference reports.PROSPERO registration number CRD42020181456.

Identifiants

pubmed: 32769874
doi: 10.1097/MD.0000000000021459
pii: 00005792-202008070-00015
pmc: PMC7592991
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

e21459

Références

N Engl J Med. 2020 Mar 26;382(13):1199-1207
pubmed: 31995857
PLoS Med. 2009 Jul 21;6(7):e1000100
pubmed: 19621070
BMJ. 2008 Apr 26;336(7650):924-6
pubmed: 18436948
BMJ. 2015 Jan 02;350:g7647
pubmed: 25555855
Int J Nurs Stud. 2015 Jan;52(1):368-79
pubmed: 24934815
J Chin Med Assoc. 2020 Mar;83(3):217-220
pubmed: 32134861
J Altern Complement Med. 2013 May;19(5):389-96
pubmed: 23317394
Support Care Cancer. 2007 Jun;15(6):597-601
pubmed: 17318592
Arthritis Rheum. 2009 Jun 15;61(6):717-24
pubmed: 19479696

Auteurs

Yu Shi (Y)

College of Acupuncture and Moxibustion and Tuina, Chengdu University of Traditional Chinese Medicine.

Dengpeng Wen (D)

College of Acupuncture and Moxibustion and Tuina, Chengdu University of Traditional Chinese Medicine.

Hui Wang (H)

Beibei District Traditional Chinese Medicine Hospital of Chongqing.

Puyue Zhang (P)

College of Acupuncture and Moxibustion and Tuina, Chengdu University of Traditional Chinese Medicine.

Yanmei Zhong (Y)

School of Medical Information Engineering, Chengdu University of Traditional Chinese Medicine.

Donghao Liu (D)

School of Basic Medical Science, Chengdu University of Traditional Chinese Medicine.

Deqi Zhou (D)

Beibei District Traditional Chinese Medicine Hospital of Chongqing.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH